GFPC
SMMT icon

Global Financial Private Client’s Summit Therapeutics SMMT Stock Holding History

Global Financial Private Client’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-5
Closed -$96 – 1371
2025
Q1 		$96 Buy
5
+4
+400% +$80 ﹤0.01% 1611
2024
Q4 		$18 Buy
+1
New +$19 ﹤0.01% 1646

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Global Financial Private Client's SMMT Position: Q2 2025 in Review

Global Financial Private Client sold out of Summit Therapeutics (SMMT) in Q2 2025, closing a stake of 5 shares — an estimated $96 sold.

Global Financial Private Client first reported a position in SMMT in Q4 2024 and held it in 2 quarters. The position peaked at $96 in Q1 2025. 238 funds tracked by Wall St. Rank hold SMMT as of Q2 2025.

  • Global Financial Private Client reported no remaining Summit Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Global Financial Private Client sold 5 Summit Therapeutics shares in Q2 2025, an estimated $96.
  • Global Financial Private Client first reported a position in Summit Therapeutics in Q4 2024 and held it in 2 quarters.
  • Global Financial Private Client's Summit Therapeutics position peaked at $96 in Q1 2025.
  • 238 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2025.

Based on Global Financial Private Client's 13F filing for Q2 2025, filed 10 Jul 2025.